Clinical Trials Logo

Still's Disease, Adult-Onset clinical trials

View clinical trials related to Still's Disease, Adult-Onset.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05432960 Withdrawn - AOSD Clinical Trials

Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)

Start date: December 2023
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to evaluate the efficacy of RPH-104 when administered at a dose of 160 mg on Day 0, Day 7, Day 21 and then once every 2 weeks (Q2W) subcutaneous (SC) in patients with Adult Onset Still's Disease (AOSD). Furthermore, the study is scheduled to investigate pharmacokinetic (PK) and pharmacodynamic (PD) parameters of RPH-104.